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Abstract
The reuse of injecting equipment in clinical settings is well documented in Africa and appears to
play a substantial role in generalized HIV epidemics. The U.S. and the WHO have begun to support
large scale injection safety interventions, increased professional education and training programs,
and the development and wider dissemination of infection control guidelines. Several African
governments have also taken steps to control injecting equipment, including banning syringes that
can be reused.
However injection drug use (IDU), of heroin and stimulants, is a growing risk factor for acquiring
HIV in the region. IDU is increasingly common among young adults in sub-Saharan Africa and is
associated with high risk sex, thus linking IDU to the already well established and concentrated
generalized HIV epidemics in the region. Demand reduction programs based on effective substance
use education and drug treatment services are very limited, and imprisonment is more common
than access to drug treatment services.
Drug policies are still very punitive and there is widespread misunderstanding of and hostility to
harm reduction programs e.g. needle exchange programs are almost non-existent in the region.
Among injection drug users and among drug treatment patients in Africa, knowledge that needle
sharing and syringe reuse transmit HIV is still very limited, in contrast with the more successfully
instilled knowledge that HIV is transmitted sexually. These new injection risks will take on
increased epidemiological significance over the coming decade and will require much more
attention by African nations to the range of effective harm reduction tools now available in Europe,
Asia, and North America.
Introduction
Medical injections performed with used syringes and nee-
dles may explain a large part of Africa's intractable AIDS
crisis, allowing cyclic transmission within high risk groups
treated at sexually transmitted disease clinics, transmitting
HIV between closed sexual networks, and infecting indi-
viduals who believe they are not at risk [1]. Blood expo-
sures of small volumes resulting from the reuse of
unsterile instruments for invasive medical and dental care
also carry a meaningful risk of HIV transmission. Signifi-
cant amounts of viable HIV survive for more than two
hours outside the body, whether on sharp surfaces
exposed to air or adhering to surfaces within used needles
and syringes [2,3]. Under rationing and staffing pressures,
this knowledge is often lacking or set aside in sub-Saharan
Africa [4].
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In South Africa and Ethiopia many health workers con-
sider injections safe when the needle is changed but the
syringe is reused, but syringe reuse is practiced even where
97% of health workers recognize single use guidelines
[5,6]. South African health workers in public maternity
and pediatric wards reused syringes under direct observa-
tion in 2005, and 30% of those surveyed did not see the
need to use a new needle for each patient [6]. The World
Health Organization (WHO) estimates that in 2000
between 17–19% of injections performed in sub-Saharan
Africa were administered unsafely [7]. Injection safety has
improved in all reporting countries over the last ten years
(Benin, Cote d'Ivoire, Ethiopia, Lesotho, Liberia, Malawi,
Mali, Rwanda, Swaziland, Tanzania, Uganda and Zimba-
bwe), but sterilization equipment for other critical items
that must be safely reused (e.g., surgical forceps, specula,
dental instruments) and appropriate training are lacking
in many formal health facilities [8].
Evidence of this role for poverty in the AIDS pandemic has
been neglected, if not actively suppressed in HIV epidemi-
ology [9]. Reverse causation has figured prominently in
the argument that associations between medical injec-
tions and HIV status do not indicate iatrogenic transmis-
sion [10]. Yet in all but one of the large cohort studies of
HIV incidence that followed HIV negative people in Africa
between 1984 and 2006, people who received medical
injections were those more likely to acquire HIV. In these
studies, the median population attributable fraction
(PAF) of HIV incidence associated with receipt of a medi-
cal injection was 19% (range 0–54%) [11].
The core public health message that AIDS is transmissible
both through sex and through needle reuse has been
taught consistently in developed nations because injec-
tion drug use (IDU) is common. Many AIDS prevention
programs in Africa have set aside injection risks in their
communications with the public, perceiving IDU as
uncommon. Introducing this information and supporting
efficacious infection control in primary health care is vital
to protecting patients from HIV as well as other blood
borne agents. In addition, a high risk group for blood
exposures needs to be acknowledged and targeted for out-
reach. Africa's growing population of IDU are, in some
communities, largely unaware that sharing needles carries
a risk of transmitting HIV.
Injection drug use in Africa
Injection drug use is no longer rare in sub-Saharan Africa.
Established along opiate and cocaine transshipment
routes up and down both coasts in the 1990s, IDU is now
prevalent even among refugees from the interior regions
of the Democratic Republic of Congo [12]. The most com-
monly injected drug in Africa is heroin, followed by
cocaine and speedball, a combination of heroin and coke
[13]. In 2006 an estimated 0.2% of African adults were
using heroin, approaching the global average [14]. In
1997 heroin consumption even exceeded marijuana con-
sumption in Ghana, cutting across all socioeconomic
groups and playing a visible role in the domestic economy
[15]. Methamphetamine use is also increasing rapidly,
and while usually smoked, it is increasingly used in com-
bination with heroin, acting as a gateway drug to more
addictive opiates [16].
IDU have been interviewed through treatment centers and
the use of snowball sampling (chain referral) in urban
Africa and large towns, but the prevalence of IDU in rural
Africa has not been assessed. National IDU prevalence
estimates from data on urban areas range up to an
astounding 1.4% in Mauritius, and prevalence is highest
among secondary students, sex workers, and prisoners in
Africa. The living situation of male IDU varies from city to
city, but most hold only temporary jobs or rely on crime
and begging to support their drug habits, and homeless-
ness is common [14,17,18]. In Ghana 48% of IDU are
unemployed and involved in petty theft to support their
drug habit [15].
Heroin use was introduced in the 1980s in a form called
"brown sugar" that is smoked (men call this "chasing the
dragon") [19]. Heroin users increasingly adopted IDU
when the supply of heroin shifted from the relatively inex-
pensive "brown sugar" variety to a more refined powder in
the 1990s [20]. Injecting is preferred over smoking for the
more expensive heroin, as a more efficient high [21].
Most IDU in Africa are male, ranging from 66% in north-
ern Nigeria to 93% in Nairobi, Kenya [17,22]. However
many African prostitutes are IDU, and injecting preva-
lence among female sex workers ranges up to 74% in
Mauritius, where one quarter of IDU are sex workers
[14,23,24]. Almost all female IDU are sex workers, and
female IDU are at greatest risk of HIV infection, with an
HIV prevalence two to ten times higher than among male
IDU [13,14,25,26]. This reflects both greater exposure
through needle sharing and greater exposure through
unprotected sex [14,18]. In Dar es Salaam, female IDU
report an average of 3 sexual partners per heroin binge,
and an average of 61.2 sex partners in the last month [27].
The average is 2.4 partners in a month for men.
Although men and women often inject under different cir-
cumstances, injecting practices are readily transferred
between them. Tanzanian sex workers share blood with
fellow users who cannot afford heroin, in a particularly
dangerous practice called "flashblood," which has
recently been reported among men as well. One user
draws blood back into the syringe after injecting heroin,
and passes the syringe to a companion, who then injectsHarm Reduction Journal 2009, 6:24 http://www.harmreductionjournal.com/content/6/1/24
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the 3–4 mL of blood [28]. This amount of blood carries a
high probability of HIV transmission.
Patterns of heroin injecting vary from daily or intermittent
use for most Nigerian IDU to frequent binging in Dar es
Salaam, Tanzania [13,28]. Heroin use now occurs in most
large towns in Kenya and Tanzania [29], and is increasing
in Cote d'Ivoire, Kenya, Mauritius, Morocco, Nigeria,
Egypt, Mozambique, South Africa and Tanzania [30]. IDU
is also highly prevalent in Ghana and the Democratic
Republic of Congo. Reports are not available for Guinea-
Bissau, now considered a narco-state [31]. Figure 1 reports
estimated IDU populations in sub-Saharan Africa, and the
prevalence of HIV among IDU for the four countries
shown where data is available. The latter can be compared
with global rates in a review that only reports IDU preva-
lence for countries also reporting the prevalence of HIV in
IDU (Figure three of Mathers et al. (2008)) [32]. Mauritius
(not shown) is a small island nation east of Madagascar in
the Indian Ocean with an estimated 22,500 IDU. Most
estimates are from the UNODC 2008 world drug report
[33].
Risks to Youth
In the town of Malindi in coastal Kenya, heroin use is
associated with drug and sex trafficking with European
tourists [34]. Here injecting is not considered "cool"
among youth ("poa" in Swahili). In contrast, in Tanzania
injecting occurs in open-air youth hangouts as well as in
more private settings [14]. One in five Tanzanian youth
surveyed in 1991 had ever tried heroin, and drug overdose
is the most common method of parasuicide in young
adults [35].
IDU is increasing among youth in most parts of Africa,
and has the potential to accelerate HIV transmission in the
very demographic with the highest HIV incidence, as sex-
ually active IDU may bridge concentrated and generalized
epidemics among young adults. Injecting behavior in
youth is associated with ease of access to heroin and
unemployment [36,37]. In a large sample of IDU in Dar
es Salaam, 76% of males lived with their parents at the
time of the interview, as did 21% of female IDU [28]. For
street children injecting is common and may be especially
dangerous. In a small sample of street children in the
Great Lakes region (in East Africa), 43.5% reported shar-
ing syringes or other instruments when using drugs [38].
In South Africa the average age at onset of heroin use is 20
[24]. One third of IDU in Kenya and Tanzania are under
age 25, compared to only 2% of IDU in Nigeria, although
in Nigeria, a relatively large proportion of tertiary students
had ever injected heroin (2.4%) and student heroin use
dates back to the 1980s [17,28,39]. In Mauritius injecting
is even more prevalent among students at 4.3% [14]. Ethi-
opian youth, by contrast, are no more likely than low-risk
groups to have ever injected drugs [23].
Crime and Prisons
Drug criminalization and drug-related crime contribute to
high IDU prevalence in African prisons. Injecting has been
reported in prisons in Cote d'Ivoire, Mauritius and Ghana.
From a human rights perspective, the threat of HIV and
hepatitis C transmission in prison warrants harm reduc-
tion interventions such as providing needles for IDU, and
this would also mitigate the role of prisons as disease res-
ervoirs in the community [40].
Drug treatment and HIV counseling could reach a large
fraction of IDU through prisons, as criminalization has
driven IDU underground and made them a hard to reach
population on the street. In Mauritius 17% of juvenile
offenders and 50% of adult offenders are IDU, and an esti-
mated 16% of IDU were imprisoned at some time in 2005
[14,19]. In Ghana in 2007, more than a third of prison
inmates had ever injected drugs, even though only 10%
had been arrested for drug trade or possession [41,42]. In
South Africa, only 1.3% of arrestees are IDU, but 17% of
IDU have been arrested in a year [43].
In Europe, Iran, Australia and Russia, harm reduction pro-
grams for prisons address the great HIV transmission risk
injecting in prison entails [44]. Similar efforts would be
appropriate in much of Africa, considering that injecting
dominates HIV transmission for inmates in drug trans-
shipment countries. In South Africa 45% of IDU in prison
are HIV positive, compared to 22% of other arrestees [24].
Among inmates in Ghana, injection drug use carries an
odds ratio of 5.7 for HIV (95% CI 2.4–12.8), making this
the strongest behavioral risk factor for HIV infection while
in prison [41]. In Cote d'Ivoire 7% of all prisoners have
shared needles while in prison, and among IDU impris-
oned in Ghana and Mauritius, 72% and 31% had ever
shared needles [14,41,45].
Needle Sharing
Knowledge that a clinically significant amount of viable
HIV can survive outside the body on blood-contaminated
instruments for several hours is not widespread in Africa
[2,3,46]. Table 1 reports the rate of needle sharing in IDU
in Africa. A large proportion of IDU regularly share
syringes, and only 25% of Nigerian IDU report knowing
that doing so carries a risk of HIV transmission. The HIV
transmission risk is known to more IDU in Kenya (73% in
Nairobi) and virtually all secondary students in Mauritius
(98.5%) [14,47]. Yet group needle ownership is common
among IDU on the Kenyan coast, and among IDU who
know they are HIV positive in Kenya up to 27.6% reported
passing their needle to someone else in the past year
[14,34]. Needle sharing with sex partners is particularlyHarm Reduction Journal 2009, 6:24 http://www.harmreductionjournal.com/content/6/1/24
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IDU prevalence and HIV prevalence among IDU in sub-Saharan Africa Figure 1
IDU prevalence and HIV prevalence among IDU in sub-Saharan Africa.Harm Reduction Journal 2009, 6:24 http://www.harmreductionjournal.com/content/6/1/24
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common among female IDU [48]. In Mombassa users
typically use the same needle for 1–3 days, and those who
store a syringe (usually at or near an injecting gallery)
report it must be hidden, as another user will often steal it
[34].
The syringes available to drug users in East Africa are large
gauge and typically damage small veins early in the injec-
tion careers of heroin users [30]. Reuse rapidly blunts the
needles. Larger gauge and blunted needles transmit larger
volumes of blood and likely pose a greater HIV transmis-
sion risk when shared.
The HIV prevalence among IDU who share needles is
high, reaching 28% in Zanzibar (vs. 5% in IDU who do
not) [49]. The IDU population in Kenya is believed to be
in decline primarily because of HIV-related mortality [34].
In Mauritius, HIV prevalence among drug users has come
to dominate the AIDS epidemic over the course of only a
few years, so that 92% of new HIV infections in 2005 were
identified in IDU [14]. In Kenya, for comparison, only
4.8% of new HIV infections are attributed to IDU,
although the HIV prevalence among IDU is five times
greater than in the general population [21].
In Dar es Salaam the HIV prevalence among IDU varied
from 0–90% across neighborhoods in 2006, averaging
57%. This variation was notably unrelated to religion
(neighborhoods with fewer or more Islamic families) or
socioeconomic status; both highest and lowest prevalence
neighborhoods were culturally mixed [25]. Here and par-
ticularly in Zanzibar, the perception that Muslim commu-
nities are not at risk from HIV for cultural reasons, and a
particular reluctance to acknowledge culturally unaccept-
able sexual behavior and injection drug use, may pose a
special challenge for harm reduction efforts. Effective
precedents in harm reduction for Muslim communities in
Uganda and Senegal demonstrate that these taboos are
not an intractable obstacle to AIDS prevention programs
[50].
Drug Policy and Services
In most African countries resources for harm reduction are
still lacking and drug use is marginalized as a crime [14].
Recent regional cooperation has led to the creation of a
data base on African NGOs active in demand reduction
activities, but overall OAU activities reflect a political pref-
erence to focus on controlling drug supply [51]. National
and regional drug policy goes beyond criminalization in
only a few instances, and international conventions are
contradictory, often curbing resources for harm reduction
on the grounds that they condone drug abuse, plainly
under pressure from the U.S. [52].
Table 2 presents the most recent IDU prevalence estimates
(among adults), and identifies existing harm reduction
policies and non-governmental organizations in countries
with reported injection drug use [33]. In 2004 in psychi-
atric hospitals, 33%, 8% and 30% of patients in Mozam-
bique, Zambia, and Tanzania respectively presented for
heroin addiction treatment [53]. Drug treatment demand
has been met only for those who can pay, except for the
services of only a handful of non-governmental organiza-
tions, and to redress this inequity public funds for drug
treatment are increasingly being shifted back to primary
health care [13]. Injection drug users are reluctant to
Table 1: Rates of needle sharing reported by IDU in five sub-Saharan African countries
Country Population Needle sharing Ref.
Kenya IDUs 27–81% (ever) [14]
Kenya Injecting heroin users in Nairobi 28–52% (past 6 months) [14,34]
Kenya Female IDUs in Nairobi 28–44% (no timeframe) [48]
Mauritius IDUs 80% (past 3 months) [14]
Mauritius Injecting sex workers 77% (ever) [14]
Nigeria Injecting heroin users 11–15% (past 6 months) [14]
South Africa Injecting heroin users in Cape Town 56–86%% (past 30 days) [14,24,43]
Tanzania Female IDUs in Dar es Salaam 6% (no timeframe) [29]
Tanzania IDUs in Zanzibar 46% (ever) [49]
IDUs – injection drug usersHarm Reduction Journal 2009, 6:24 http://www.harmreductionjournal.com/content/6/1/24
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Table 2: IDU prevalence in 2008 and harm reduction resources in sub-Saharan Africa [33,55,56]
Country IDU prevalence Harm reduction NGOs and government programs
Angola 0.18% NGO(s) involved in rehabilitation
CAR 0.09% NGO(s) involved in rehabilitation
Congo 0.08% Mental health policy includes rehabilitation
Cote d'Ivoire 0.08% Mental health policy includes rehabilitation
NGO(s) involved in rehabilitation
DRC 0.6% Mental health policy includes rehabilitation
NGO(s) involved in rehabilitation
Ethiopia 0.08% None identified.
Ghana 0.05% Mental health policy includes rehabilitation
Kenya 0.18% NGO: Omari Project
Government programs include opioid substitution
Liberia 0.2% NGO: Student Aid Liberia Inc.
Mauritius 1.8% NGO: Prevention Information et Lutte contre le Sida
Government programs include needle exchange and methadone treatment
Mozambique Unknown Government programs include drug treatment at psychiatric hospitals
NGO(s) involved in rehabilitation
Namibia 0.08% NGO(s) involved in rehabilitation
Niger 0.09% NGO(s) involved in rehabilitation
Nigeria 0.35% NGO: Nigerian Friends for Harm Reduction
Senegal 0.08% Mental health policy includes rehabilitation
NGO(s) involved in rehabilitation
Sierra Leone 0.03% NGO(s) involved in rehabilitation
Somalia 0.09% NGO(s) involved in rehabilitation
South Africa 0.15% Government programs include opioid substitution and demand reduction
NGO(s) involved in rehabilitation
NGO: RAVE Safe
Tanzania 0.09% Government programs include counseling and rehabilitationHarm Reduction Journal 2009, 6:24 http://www.harmreductionjournal.com/content/6/1/24
Page 7 of 11
(page number not for citation purposes)
present for public services, however, fearing they will be
turned over to the authorities [54-56].
In Tanzania, drug policing is highly visible, but demand
reduction has not received the same attention, and injec-
tion drug use has been driven underground [57]. Some 30
heroin addicts are received for emergency psychiatric serv-
ices in Muhimbili Medical Center in Dar es Salaam every
year [58]. In 2004 both the President's Emergency Plan for
AIDS Relief (PEPFAR) and USAID backed a community
based outreach program to reach IDU in Tanzania and
refer them to voluntary counseling and testing (VCT) and
HIV and drug treatment [57]. Addiction services are avail-
able from NGOs and mental health and family coun-
seling, and in psychiatric agricultural rehabilitation
villages [55,57]. These villages, developed in 1969, pro-
vide occupational therapy as well as mental health serv-
ices, and importantly they are also self-supporting.
Federal support for public health services has contracted
dramatically under structural adjustment policies, under-
mining both primary health care safety and services for
drug treatment.
In coastal Kenya a small service for heroin addicts, the
Omari Project, has incorporated injection safety into its
counseling sessions [34]. However access to addiction
services in Kenya is limited primarily to residential facili-
ties serving males who can pay for care [59]. Most drug
treatment in Kenya goes on at government hospitals
instead.
In South Africa drug treatment has been accessible mostly
to white IDU who can make co-payment for clinical serv-
ices [14,60]. Public funding for drug treatment is being
scaled back and integrated into primary health care net-
works to redress this inequality, as IDU prevalence
increases among colored and black South Africans [14].
Here demand reduction activities have focused on at-risk
women, and on youth (e.g., the "Ke Moja – No thanks,
I'm fine!" drug awareness campaign, and a classroom-
based leisure, life-skill and sexuality education curricu-
lum, "HealthWise") [60]. Allowing IDU access to new
injecting equipment is not promoted, however. In South
Africa 48% of IDU reported having been denied needles
within the last year at a hospital or pharmacy [14].
Mauritius' 2006 HIV and AIDS Act established Africa's
first needle exchange and methadone maintenance pro-
gram [57]. This reaction to explosive HIV transmission
among IDU in an otherwise low-prevalence population
may not be duplicated in countries with greater HIV prev-
alence. Through early 2009, there are no other needle
exchange programs in sub-Saharan Africa [61]. However,
in 2007 the Sub-Saharan African Harm Reduction Net-
work (SAHRN) was formed, and NGOs, researchers and
UN representatives from eleven African countries met to
discuss drug harms and policies [62].
Medical injections and HIV in Africa
Estimates of the relative importance of unsafe medical
injections in the AIDS pandemic vary across orders of
magnitude. This is because the probability an individual
unsafe medical injection will transmit HIV is not known,
and estimates supported in the peer reviewed literature
range from 0.1% to 6.9%. These estimates are drawn from
four types of empirical evidence: (1) rates of HIV infection
from needle-stick injuries (any accidental scratch or jab
commonly injuring a health worker while administering
an injection to an HIV infected patient) [63]; (2) HIV inci-
dence among IDU who share needles [63-65]; (3) retro-
spective analysis of large iatrogenic HIV outbreaks [66];
and (4) laboratory examinations of used syringes col-
lected in the field [67,68]. Although interpretation of the
available evidence is divided, these four types of estimates
of the probability a medical injection will transmit HIV all
include the range from 1.9–2.3%. The WHO models the
probability of transmitting HIV as 1.2% [69].
NGO(s) involved in rehabilitation
PEPFAR/USAID providing referral for voluntary HIV counseling and testing and for drug treatment
Uganda 0.1% Mental health policy includes rehabilitation
NGO(s) involved in rehabilitation
Zambia 0.18% Government programs include drug treatment at psychiatric hospitals
NGO(s) involved in rehabilitation
Zimbabwe 0.09% NGO(s) involved in rehabilitation
CAR – Central African Republic, DRC – Democratic Republic of Congo (formerly Zaire), IDU – injection drug use
Table 2: IDU prevalence in 2008 and harm reduction resources in sub-Saharan Africa [33,55,56] (Continued)Harm Reduction Journal 2009, 6:24 http://www.harmreductionjournal.com/content/6/1/24
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HIV prevalence is stabilizing in much of sub-Saharan
Africa, but the AIDS burden on health care is still increas-
ing as more patients progress to advanced HIV disease,
unfortunately outpacing the availability of antiretroviral
drugs. Updating the WHO's model of the global burden of
disease from unsafe injections (describing the epidemic in
2000), to account for the elevated clinical prevalence of
HIV, an estimated 12–17% of new HIV infections in 2007
could be attributed to unsafe medical injections alone
[70]. Hospital acquired infections from other invasive
procedures have not been estimated, but assisted delivery
has been linked to excess HIV infections across Africa and
visible blood has been observed on arterial forceps,
sutures and other equipment that contacts patients in
maternity and pediatric wards [71,7].
Hundreds of recorded cases of HIV positive children with
HIV negative mothers indicate that the harm to children
has been substantial [72]. Today most African countries
use only auto-disable (self-destructing, non-reusable)
syringes for immunizations, but other risks to children
that persist include invasive procedures, dental care, and
non-immunization injections. In South Africa auto-disa-
ble syringes are not required for immunizations, and the
HIV prevalence in children is too high to be explained by
mother-to-child transmission alone [73]. Moreover the
incidence of HIV in children no longer breastfeeding and
already immunized (ages 2–14) is 0.5% per year in South
Africa [74].
The WHO's model of injection risks in the year 2000 esti-
mates that African adults receive on average 2.1 injections
per year, and that almost one in five injections are unsafe
[69]. More recent data on unsafe injection frequency,
available from 12 of the 14 countries in Table 3, demon-
strate significant improvement. The probability that an
adult will receive an unsafe medical injection in a year var-
ies from 0.1% to 22% (lowest and highest in Lesotho and
Rwanda), but the median is only 4.4% [8]. In these coun-
tries unsafe injection risks are generally greater for men,
for the poor, and in rural areas [8].
More than a third of the population of sub-Saharan Africa
(living in Nigeria, Uganda, Malawi, the Democratic
Republic of Congo, and Burkina Faso) should be at much
lesser risk of unsafe injections, as they are protected by
national bans on the use of disposable syringes that can
be unsafely reused. Other injection safety interventions
Table 3: Unsafe injection frequency and sterilization equipment coverage in sub-Saharan Africa 2002–2007
Country, survey year Unsafe injections per person in past year Clinics with sterilization equipment (%)
Benin, 2006 4.2 No information
Cote d'Ivoire, 2005 5.3 No information
Ethiopia, 2005 7.6 No information
Ghana, 2002 No information 67
Kenya, 2004 No information 60
Lesotho, 2004 0.1 No information
Liberia, 2007 7.8 No information
Malawi, 2004 3.9 No information
Mali, 2006 1.7 No information
Rwanda, 2005/2007 22.0 83
Swaziland, 2006 4.6 No information
Tanzania, 2005/2007 3.3 65
Uganda, 2005/2007 5.3 68
Zimbabwe, 2006 3.3 No informationHarm Reduction Journal 2009, 6:24 http://www.harmreductionjournal.com/content/6/1/24
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have been funded under the President's Emergency Plan
for AIDS Relief (PEPFAR) through Making Medical Injec-
tions Safer projects. These interventions and those of the
WHO's Safe Injection Global Network (SIGN) have
reduced the frequency of unnecessary injections, reduced
the risks posed by improper disposal of sharp medical
waste, and produced and disseminated infection control
guidelines to improve clinical practice. However these
programs ignore larger problems with infection control
capacity in African health care settings, as reported in
Table 3[8].
AIDS researchers and health workers under rationing pres-
sures face a conflict of interest in acknowledging and
investigating risks to transmit HIV from patient to patient,
as this may undermine public confidence in the compe-
tence and motivation of researchers and health workers,
leading to under-utilization of essential health services
and to preventable morbidity and mortality [75]. Minis-
tries of Health have a duty to resolve this ethical dilemma
while scaling up primary health care services. Informing
patients and health workers of the seriousness of HIV
transmission risks in minor blood exposures and equip-
ping the health care system to cope with the full demands
of infection control will be necessary to avert further iatro-
genic HIV transmission. These responsibilities go beyond
injection safety interventions such as using only auto-dis-
able (self-destructing, non-reusable) syringes.
WHO assurances that medical injection risks are minimal
are not credible, and reflect a pattern of suppressing evi-
dence that heterosexual sex explains less than 90% of HIV
transmission in Africa [1]. Where evidence of harm is egre-
gious, leading AIDS researchers have invoked a relativistic
standard, characterizing a 1% prevalence of HIV positive
children with HIV negative mothers (in six major African
cities) as representing a "low" risk of patient-to-patient
HIV transmission [76]. In a crude irony concerning the
social construction of disease, the WHO is defending a
90% estimate that was arrived at by a process of elimina-
tion; that is, not on the basis of positive evidence that 90%
of HIV infections can be traced to sex in Africa [77]. In fact
infection tracing has been consistently avoided in cases of
reportedly non-sexual HIV transmission identified in epi-
demiological research. Self-reported virgins with HIV, and
research subjects with incident infections who claim not
to have had sex over the study interval, have been classi-
fied as evincing "social desirability bias," by denying epi-
demiologically implicit sexual behavior.
Blood exposures were of interest to HIV epidemiologists
in the 1980s, before a consensus focusing on heterosexual
transmission was established for Africa, but even transfu-
sion risks were considered intractable at an early stage.
Early Western experts' statements concerning the place of
infection control in HIV prevention efforts in Africa were
highly pessimistic [1]. For example, "one cannot hope to
prevent reuse of disposable injection equipment when
many hospital budgets are insufficient for the purchase of
antibiotics." This statement appears in an important 1986
article whose authors include the heads of WHO's Global
Programme on AIDS and later UNAIDS for most of the
next 21 years [77]. The problem has not worked itself out,
and cannot wait for the day when rationing does not limit
the options of health workers in sub-Saharan Africa.
Conclusion
Injection drug use has increased rapidly during the recent
past throughout sub-Saharan Africa, with the greatest
increase in Mauritius, and the greatest numbers of IDU in
West-Central Africa. Projecting a similar rate of increase
through the year 2015, IDU prevalence could reach 0.24%
in Southern Africa, 0.08% in East Africa, and 0.19% in
West-Central Africa. For comparison, in the U.S. the prev-
alence of heroin use (primarily administered by injecting)
has stabilized at around 0.2%,78,33 and the prevalence of
methamphetamine injecting has risen to 0.3% of adults
under 50 [33,78,79]. Although IDU prevalence is greatest
and expanding most quickly in major drug transshipment
countries, habitual injecting has penetrated far beyond
the periphery of major ports and airports, observed even
among refugees from the interior of the Democratic
Republic of Congo.
HIV prevalence among IDU can also be expected to
increase, as the scant drug treatment and harm reduction
activities in sub-Saharan Africa are unlikely to impact
upward trends that have been documented in Nigeria and
South Africa. Interventions to raise awareness of the HIV
transmission risk from sharing needles are needed, partic-
ularly in Nigeria. Outreach (1) to out-of-school youth as
well as students, (2) to female sex workers' clients as well
as at-risk women, and (3) to unemployed adults and the
homeless, as well as IDU who can afford residential treat-
ment, will be needed. Support for harm reduction spend-
ing may hinge on recognition that concentrated HIV
epidemics among IDU are relevant to the spread of HIV
among sexually active young adults in Africa's generalized
epidemics.
For the protection of patients, accurate information that
HIV can survive outside the body in blood-contaminated
instruments and on sharps must be taught, and suspected
iatrogenic HIV cases should be traced through the impli-
cated clinics and investigated to identify and prevent other
cases. These efforts will in no way detract from the mes-
sage that HIV is sexually transmitted, even if it is evident
that sexual transmission explains less than 90% of infec-
tions in Africa. Public awareness of HIV transmission risk
from other prevalent skin-piercing procedures (such asHarm Reduction Journal 2009, 6:24 http://www.harmreductionjournal.com/content/6/1/24
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tattooing, shaving with an unsterilized razor, or unsterile
dental care) is also poor in Africa, and should be
addressed simultaneously [46,80,81]. Introducing this
information and supporting effective infection control in
primary health care could significantly reduce HIV trans-
mission in Africa.
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